ArticleFrontiers in nutrition2025
Prognostic value of the lactate dehydrogenase to albumin ratio in cancer patients.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A predictive model for immunotherapy in extensive-stage small cell lung cancer based on peripheral blood.Journal of thoracic disease · 2026Article
- Predictors and mortality in PCR-positive pneumocystis pneumonia among non-HIV patients.BMC infectious diseases · 2026Article
- Prognostic value of lactate dehydrogenase-to-albumin ratio in metastatic/recurrent pancreatic cancer treated with first-line gemcitabine plus nab-paclitaxel: a single-center retrospective cohort study.Journal of gastrointestinal oncology · 2026Article
- Preoperative Lactate Dehydrogenase-to-Albumin Ratio as a Tumor-Host Biomarker of Early Recurrence and Survival in Resected Pulmonary Neuroendocrine Carcinomas: A Multicenter Observational Cohort Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Pretreatment Lactate Dehydrogenase-to-Albumin Ratio and Clinical Outcomes in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.Journal of clinical medicine · 2026Article
- Uric Acid-Driven Biomarkers and Clinical Outcomes in Metastatic Pancreatic Cancer: A Multicenter Real-World Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Lactate dehydrogenase-to-albumin ratio as a potential prognostic indicator in glucocorticoid-treated severe pneumonia: a multicenter retrospective study with external validation.Frontiers in immunology · 2026Article
- The lactate dehydrogenase-to-albumin ratio is independently associated with moderate-to-severe tubulointerstitial fibrosis in patients with IgA nephropathy.Frontiers in nephrology · 2026Article
- Prognostic value of the lactate dehydrogenase-to-albumin ratio (LAR) combined with clinicopathological indicators for predicting outcomes in locally advanced cervical cancer undergoing concurrent chemoradiotherapy: a retrospective cohort study and nomogram development.American journal of cancer research · 2026Article
- Baseline inflammatory and metabolic indicators associated with early PD-1 inhibitor resistance in advanced cervical cancer: a retrospective cohort study.Frontiers in medicine · 2026Article
- Lactate Dehydrogenase to Albumin Ratio as a Predictor of Severe Community-Acquired Pneumonia in Patients Aged 60 years and Above: A Retrospective Cohort Study.Infection and drug resistance · 2026Article
- Disease-specific divergence of inflammatory and metabolic biomarkers in neurocritical neuromuscular disorders.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to explore the prognostic relevance of the lactate dehydrogenase-to-albumin ratio (LAR) in cancer patients. Methods: A comprehensive literature search was conducted across PubMed, EMBASE, and the Cochrane Library for studies published before March 15, 2025. The primary outcomes included pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for overall survival (OS), progression-free survival (PFS), and recurrence-free survival (RFS). In addition, a retrospective cohort of 71 hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors at our institution was analyzed to assess the prognostic impact of baseline LAR on OS and PFS. Results: Eighteen studies comprising 8,335 patients were incorporated into the meta-analysis. Elevated LAR was consistently associated with poorer outcomes: OS (HR: 2.02, 95% CI: 1.74-2.34, Conclusion: These findings underscore the prognostic value of pretreatment LAR in cancer patients. Integrating LAR into clinical decision-making may aid clinicians in enhancing risk stratification and personalizing treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.